Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Pharmacyclics Incorporated (PCYC) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.4%. By the end of trading, Pharmacyclics Incorporated rose $2.88 (5.4%) to $55.93 on average volume. Throughout the day, 781,982 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 736,200 shares. The stock ranged in a price between $53.35-$56.08 after having opened the day at $53.51 as compared to the previous trading day's close of $53.05. Other companies within the Health Care sector that increased today were: Neuralstem (CUR), up 19.2%, Cyclacel Pharmaceuticals (CYCC), up 18.3%, Idera Pharmaceuticals (IDRA), up 13.5%, and Alphatec Holdings (ATEC), up 13.4%.

• EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $3.76 billion and is part of the drugs industry. The company has a P/E ratio of 38.6, above the S&P 500 P/E ratio of 17.7. Shares are up 265% year to date as of the close of trading on Friday. Currently there are seven analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good.

• You can view the full Pharmacyclics Ratings Report.

On the negative front, Oxygen Biotherapeutics (OXBT), down 13.6%, Biocryst Pharmaceuticals (BCRX), down 12.2%, Delcath Systems (DCTH), down 9.3%, and Globus Medical Inc Class A (GMED), down 8.8%, were all laggards within the health care sector with Hologic (HOLX) being today's health care sector laggard.

• Use our health care section to find sector-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

• Find other investment ideas from our top rated ETFs lists.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.

For more information on Pharmacyclics Incorporated click any of the following:

• Pharmacyclics Incorporated Stock Price

• Pharmacyclics Incorporated Analyst Ratings

• Pharmacyclics Incorporated Key Stats & Profile

• Pharmacyclics Incorporated Earnings

• Pharmacyclics Incorporated Ratio Comparison

• Pharmacyclics Incorporated Growth Rates

• Pharmacyclics Incorporated Balance Sheet

• Pharmacyclics Incorporated Cash Flow

• Pharmacyclics Incorporated Income Statement